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Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with o5% 5-year survival, in which standard
chemotherapeutics have limited benefit. The disease is associated with significant intra- and peritumoral inflammation and failure of
protective immunosurveillance. Indeed, inflammatory signals are implicated in both tumour initiation and tumour progression. The major
pathways regulating PDAC-associated inflammation are now being explored. Activation of leukocytes, and upregulation of cytokine and
chemokine signalling pathways, both have been shown to modulate PDAC progression. Therefore, targeting inflammatory pathways
may be of benefit as part of a multi-target approach to PDAC therapy. This review explores the pathways known to modulate
inflammation at different stages of tumour development, drawing conclusions on their potential as therapeutic targets in PDAC.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most
lethal and aggressive of all malignancies, and as the 5th most
common cause of cancer death in the United Kingdom represents a
significant therapeutic challenge. Patients with potentially resect-
able disease are in the minority (10–15%) because of extensive local
spread or metastatic disease at presentation (Sener et al, 1999).
Despite surgery, the 5-year survival rate is a dismal 3–5% due to
secondary recurrence.
The European Study of Pancreatic and Ampullary Cancer
(ESPAC) trials have consistently demonstrated a modest survival
benefit associated with post-operative adjuvant therapy, with
fluorouracil and gemcitabine equally effective (Neoptolemos
et al, 2010). Unfortunately, although a subset of patients who
receive gemcitabine have tumours responsive to these drugs, a
significant number develop resistance (Liss and Thayer, 2012).
Despite similar presentation and histological appearance, these
tumours are biologically diverse and exhibit complex molecular
and cellular heterogeneity, however, aggressive progression is
common to all (Vincent et al, 2011). Indeed, recent elegant lineage
tracing studies in mice have identified that cells may disseminate
from pancreatic lesions even before the primary tumour is
histologically evident, leading to a call for new approaches to
PDAC therapy (Rhim et al, 2012; Tuveson and Neoptolemos,
2012). Management algorithms for PDAC must change, taking
into account tumour biology, and stratifying therapy on an
individual patient basis while pursuing strategies to combat
recurrence in patients following surgical resection. The dependence
of PDAC on certain crucial inflammatory mediators suggests that
targeting of these central roles may hold hope for effective
therapies.
The following review focuses on the failure of tumour
immunosurveillance mechanisms in PDAC initiation and the
accumulation in the pancreas of immunosuppressive cells that
permits tumour progression, and discusses how failure of
immunosuppression may be addressed therapeutically. We
describe how tissue damage combined with oncogene activation
(KRAS), loss of tumour suppressor genes (TSGs) (TP53 and
SMAD4), deregulation of chemokines (CXCR2 ligands) and
cytokines (interleukin (IL)-6, IL-1a), activation of downstream
effectors (STAT3, NF-kB), and concurrent leukocyte recruitment
by the tumour are key events in both initiation and progression of
PDAC. Throughout, we consider the potential of these inflamma-
tory mediators as therapeutic targets in PDAC taking into account
the results of preclinical and clinical research to date.
IMMUNE INFILTRATION DURING PDAC INITIATION AND
PROGRESSION
In healthy individuals, the adaptive immune system is responsible
for tumour immunosurveillance, through which the host can
identify, mount a response to, and destroy tumour cells.
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Tumorigenesis represents a failure of adaptive immunity, as in
order for malignant transformation to progress unchecked tumour
cells must escape this surveillance. The immune response to cancer
is a dynamic process and can also initiate pathways that are in fact
pro-tumorigenic. Even then a fine balance exists, as tumour
progression is complex, reliant on interactions between the tumour
and its activated microenvironment (Baumgart et al, 2011).
In early tumorigenesis, immune cells, including CD8þ T cells,
detect danger signals from cancer cells and respond by eliminating
these cells, leading to tumour immunogenicity. Dendritic cells are
key regulators of tumour-specific immune responses in that they
function as antigen presenting cells, activating CD8þ cytotoxic T
lymphocyte (CTL) responses or stimulating CD4þ T cells through
interaction with MHC class II molecule–antigen complexes (Finn
2008). In pancreatic tumorigenesis, Hiraoka and colleagues
reported that chemokine (C-X-C motif) ligand 17 (CXCL17) was
responsible for infiltration of immature dendritic cells while the
intercellular adhesion molecule (ICAM2) permitted killing of
tumour cells by CD8þ cells. During evolution from precursor
lesions to PDAC they found that the host immune response was
tempered and tumours developed immune tolerance by down-
regulating CXCL17 and ICAM2 (Hiraoka et al, 2011). Interest-
ingly, Dillman and colleagues recently described the value of
reintroducing dendritic cells loaded with antigen from autologous
irradiated tumour cells in metastatic melanoma. Those patients
who received this dendritic cell vaccine survived significantly
longer than those irradiated with tumour cell vaccine alone
(Dillman et al, 2011). Conversely, in PDAC, blockade of Toll-like
receptor 4 (TLR4) signalling enhanced dendritic cell-mediated
recruitment of T helper 2 (Th2) CD4þ cells, and this resulted in
increased pancreatic inflammation and accelerated tumour pro-
gression (Ochi et al, 2012). Thus, depending on antigenic stimulus,
dendritic cells can both promote and inhibit tumour progression.
Once tumour immune surveillance is overcome, the composi-
tion of the immune infiltrate changes and a pro-tumorigenic
leukocyte profile emerges (Figure 1). It is not yet fully understood
how these different pro and anti-tumoural components of the
immune system are engaged, however, signals in the tumour
microenvironment, including IL-10, can prevent dendritic cell
activation, thus dampening the adaptive immune response (Koido
et al, 2010). T cells can be both tumour suppressing and promoting
depending upon their downstream target cells. CD4þ cells,
particularly T regulatory cells and Th2 cells, increase in number
over the course of pancreatic cancer progression, whereas CTL cells
decrease (Clark et al, 2007). This dynamic circumstance leads to a
progressive accumulation of immunosuppressive cells that inhibit
the anti-tumoural immune response. In tumours infiltrated by
T regulatory cells both innate and adaptive immunity may well be
suppressed, while myeloid-derived suppressor cells (MDSCs) can
also subdue anti-tumour activity (Gabrilovich and Nagaraj, 2009).
In this milieu of tumour cell killing and escape, the immune
system must clear damaged tissue. Neutrophils move into tissues
under the control of chemokine signalling, particularly CXCR2.
Though short lived, neutrophils have the potential to induce
significant tissue remodelling. Fridlender et al (2009) demonstrated
that following transforming growth factor-b (TGF-b) blockade,
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Figure 1. The role of inflammation in PDAC Initiation. PDAC evolution occurs from PanIN 1 through 3 to invasive PDAC with progressive
accumulation of desmoplastic stroma (H&E, top panels). The leukocyte infiltration surrounding lesions changes as PanINs progress.
Tumour-associated macrophage infiltration increases early in PDAC tumorigenesis as demonstrated by F4/80 immunohistochemistry (second row).
Neutrophils (visualised by MPO staining) are abundant around developing PanIN lesions but sporadic within developed tumours (third row).
Varying quantities of T cells are present within both PanINs and PDAC, as shown by CD3 immunohistochemistry (bottom row).
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neutrophils exhibited an anti-tumour phenotype termed N1. Both
neutrophils and MDSCs are Gr1þ , CD11bþ cells. The
progressive accumulation of MDSCs in PDAC is widely recog-
nised, while their immunosuppressive effect is clear. They are
known to have the capacity to differentiate into both neutrophils
and macrophages (Kusmartsev et al, 2005), and it has been
suggested that pro-tumorigenic N2 neutrophils (TANs) may
differentiate from MDSCs of splenic origin. Indeed two groups
have demonstrated that in response to oncogenic Kras-dependent
GM-CSF secretion, MDSCs are recruited to the tumour micro-
environment where they have a role in suppressing CTL cell action
and thus permitting tumorigenesis (Bayne et al, 2012; Pylayeva-
Gupta et al, 2012). When GM-CSF was suppressed, MDSCs failed
to infiltrate the tumour microenvironment, and tumour growth
was limited by infiltrating CTL cells. Furthermore, this effect was
fully rescued by CTL depletion. Activated neutrophils also have the
capacity to cause tissue damage via the release of matrix
metalloproteinases (MMPs), while production of reactive oxygen
species may promote mutagenesis. Reactive oxygen species have
been implicated in the activation of NF-kB, which has been
intimately associated with the inflammatory response and PDAC
progression (DeNicola et al, 2011).
Tumour-associated macrophages (TAMs) are present in early
PDAC and persist throughout progression, representing an
important component of the PDAC-associated leukocyte infiltrate
(Clark et al, 2007). Intriguingly, TAMs can evolve to exhibit an M2
phenotype that is pro-tumorigenic in terms of promotion of
growth and angiogenesis, and suppression of adaptive immunity
(Sica and Mantovani, 2012). It is thought that this polarisation of
macrophages from a tumour-suppressive M1 phenotype is initiated
by cytokine signals, including IL-10 and TGF-b, received from T
regulatory and tumour cells (Sica and Mantovani, 2012). This
situation can be thought of as self-reinforcing, as production of
pro-angiogenic molecules, including vascular endothelial growth
factor (VEGF), attracts yet more macrophages to the tumour
microenvironment, further enhancing angiogenesis. The plasticity
of TAMs makes them an ideal therapeutic target for manipulation
to generate an anti-tumour response.
Understanding the regulation of cancer immunosurveillance
may help efforts to promote adaptive immune responses against
PDAC, whereas the plasticity of TAMs and TANs may provide
therapeutic opportunities for the promotion of an anti-tumour
phenotype. There are examples where TAMs have been seen to
elicit cancer-destructive properties. Hagemann et al (2008) have
suggested that macrophages may be re-educated towards an anti-
tumour function through control of NF-kB activity. Triggering a
‘good’ innate immune response is a potential goal for anti-cancer
therapy with the activation of M1 macrophages and inhibition of
MDSCs and T regulatory cells as the important objectives.
Antibodies against M2 macrophages and regulatory T cells are
now available for trial in preclinical models, while measures to
harness the immune system to eradicate tumour cells are being
considered. An excellent example was recently provided in a cohort
of metastatic PDAC patients who received CD40-targeting
monoclonal antibodies in addition to gemcitabine (Beatty et al,
2011). CD40 activation, somewhat unexpectedly, led to macro-
phage-dependent tumour regression. Promotion of properties of
the adaptive immune system that protect us from malignancy in
health holds promise for future trials.
STROMAL CHANGES DURING TUMORIGENESIS
In addition to immune cells other stromal elements have key roles
in PDAC pathogenesis. Paracrine signalling through different
molecules including TGF-b, VEGF, hepatocyte growth factor,
Sonic hedgehog (Shh), epidermal growth factor, fibroblast growth
factors and insulin-like growth factors signal to the adjacent
microenvironment, and in particular pancreatic stellate cells
(PSCs). This interaction activates PSCs and is primarily responsible
for fibrosis in PDAC (Neesse et al, 2011). Pancreatic stellate cells
are also implicated in local tumour growth, in addition to their
ability to travel to distant sites and support metastatic formation
(Neesse et al, 2011). Furthermore, PSCs secrete factors into the
microenvironment such as secreted protein acidic and rich in
cysteine (SPARC), a protein which is associated with cell migration
and wound healing, and high levels of which are associated with
poor outcome in PDAC (Infante et al, 2007). Interestingly
albumin-bound Paclitaxel (nab-paclitaxel) has been observed to
bind SPARC-expressing fibroblasts, possibly providing a mechan-
ism for targeting this specific cell type. Clinical trial of nab-
paclitaxel in PDAC has shown some promise in combination with
gemcitabine (Von Hoff et al, 2011), however, the full role of
SPARC in modulating the tumour microenvironment is unclear,
with few changes seen in tumour stroma when preclinical PDAC
models were treated (Frese et al, 2012).
The dense, avascular, collagenous extracellular matrix that
constitutes the majority of the tumour bulk in human PDAC has
been shown to mechanically block the vascular delivery of
chemotherapeutic agents to tumours in preclinical models
(Neesse et al, 2011). It is anticipated that drugs that attack stromal
elements responsible for tumour maintenance will be of clinical
benefit. Thus far, clinical trials assessing anti-stromal therapies
including anti-MMP and VEGF inhibitors such as Bevacizumab
have proven disappointing (Neesse et al, 2011). Among others, Shh
signalling through Smoothened (Smo) has been implicated in the
coordination of tumour-stromal crosstalk in PDAC. The clinical
trial based on the work of Olive et al (2009), who showed modest
prolongation of survival of mice with PDAC following Smo
inhibition in combination with gemcitabine, has been stopped due
to better survival in the control arm (clinicaltrials.gov). In future,
perhaps only trials demonstrating regression in primary tumour
size and alteration of metastatic potential in murine models should
be considered for trial in humans. However, there remains a belief
that combating collagenous elements of PDAC stroma and
promoting intra-tumoural vascularity will help delivery of standard
chemotherapeutics to tumour cells. Tumours are dependent on
both the protective effect of the stroma and interactions with
stromal cells for progression. Hyaluronan has been identified as a
key determinant of the stromal matrix with hyaluronidase
treatment causing profound effects on tumour stroma in murine
models of PDAC (Jacobetz et al, 2012; Provenzano et al, 2012).
These drugs have also been shown to expand tumour vasculature
and permit access of chemotherapeutics to the pancreas providing
promise for ongoing clinical trials.
THE IMPORTANCE OF INFLAMMATION IN PDAC
DEVELOPMENT
Mutations in the KRAS oncogene are presumed responsible for
PDAC initiation and seen in the earliest PanIN lesions in nearly all
cases. As these lesions progress from PanIN2 to PanIN3, mutations
in the tumour suppressors TP53, CDKN2A, DPC4/SMAD4 and
BRCA2 are observed at varying frequencies, leading to invasive
PDAC (Hruban et al, 2000). Recently, attention has switched to the
elucidation of the role played by inflammation in the evolution of
PDAC. Mouse models have been useful in demonstrating the
importance of local inflammation in pancreatic tumorigenesis. The
Barbacid lab has shown that experimentally induced chronic
pancreatitis (CP) combined with targeted expression of oncogenic
mutant KrasG12V to pancreatic acini, cooperate to induce PDAC
formation (Guerra et al, 2007). Lee and Bar-Sagi (2010)
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demonstrated that on a background of inflammation, rather than
activating senescence, Kras mutation led to decreased expression of
Ink4a and a block in senescence, leading the authors to conclude
that mutation of Kras in the presence of a pre-existing
inflammation would lead rapidly to tumorigenesis. These studies
suggest that PDAC can occur on a background of pre-existing,
possibly subclinical, pancreatic inflammation. The identification of
patients at risk of low-level pancreatic inflammation could allow
clinical application of these findings in future.
Interestingly, patients with CP have an increased risk of PDAC,
though the majority of patients do not develop cancer (Hezel et al,
2006). Patients presenting to clinics with CP represent the extreme
end of the spectrum of pancreatic inflammation. Indeed, these
patients have little functional pancreas as the majority is replaced
with fibrous tissue (Kloppel 2007). Interestingly a high proportion
of these patients carry KRAS mutations yet fail to develop PDAC,
an observation that remains poorly explained (Rivera et al, 1997).
Potentially, the mutational stress that low-grade pancreatic
inflammation causes could create a more tumour-prone environ-
ment than the high-grade inflammation associated with CP.
Obesity, alcohol excess and particularly smoking have long been
associated with low-grade systemic inflammation and predisposi-
tion to PDAC development, reviewed by Charkraborty et al (2011).
Indeed in high-risk patient groups, including hereditary pancrea-
titis and familial PDAC families, smoking decreases the age of
PDAC onset by an average of 20 years (Lowenfels et al, 1993).
Although smoking is likely to result in an increased mutational
burden, the tumour-promoting potential of the accompanying
systemic inflammation should not be ignored. Indeed C-reactive
protein (CRP), a marker of systemic inflammation, is a negative
prognosticator in PDAC following resection, while systemic
activation of COX-2, NF-kB, nitric oxide synthetase, production
of IL-1, IL-6, IL-8 and TNF-a, and free radical oxygen formation
have all been associated with PDAC progression (Farrow et al,
2004). Downregulation of systemic inflammation by generic anti-
inflammatories are already being trialled in other cancers.
Epidemiological evidence does not conclusively support the use
of aspirin or COX-2 inhibition in PDAC prevention (Tan et al,
2011), however, these widely available drugs may be of use in
groups of PDAC patients with evidence of significant inflammation
generated in response to their tumours, as measured by CRP.
Inhibition of certain systemic mediators of inflammation has had
some success in preclinical models. Pdx1-Cre KrasG12D mice fed
with COX-2 inhibitor showed a significant delay in PanIN
progression (Funahashi et al, 2007). However, studies have failed
to identify a role for COX inhibition in PDAC therapy. Despite
initial promise, a phase II study of Celecoxib in addition to
gemcitabine and cisplatin for advanced PDAC showed no benefit
over chemotherapy alone (El-Rayes et al, 2005). In future trials,
patients should be selected based upon COX-2 expression status to
avoid missing potential therapeutic benefit.
PDAC-ASSOCIATED MUTATIONS SUSTAIN AN
INFLAMMATORY MICROENVIRONMENT
The mounting of a response to tumour threat or injury is not the
only way in which the immune system can become pathologically
activated in PDAC. Initiating KRASmutations induce upregulation
of inflammatory pathways in PDAC, and downstream of KRAS the
RAF signalling pathway induces production of chemokines and
cytokines that may in themselves be pro-tumorigenic, including
chemokines CXCL1 and CXCL8, the major ligands for CXCR2
(Balkwill, 2012). The oncogenic transcription factor c-Myc, also
activated in tumours, promotes cell-autonomous proliferation and
is key to tumour microenvironment remodelling via stimulation of
inflammatory cells and cytokine production (Balkwill, 2012).
Ochi et al recently showed high expression of Toll-like receptor
7 (TLR7) in PDAC. They elegantly demonstrated in a murine
model that TLR7 ligation accelerated pancreatic tumorigenesis via
upregulation of inflammatory cascades including STAT3 and NF-
kB pathways. Toll-like receptor 7 blockade protected against
carcinogenesis and when mice lacking TLR7 exclusively within
their inflammatory cells were generated they were completely
protected from carcinogenesis (Ochi et al, 2012). Toll-like receptor
7 inhibition may have a role in combating the tumour
microenvironment in PDAC by preventing signalling through
downstream inflammatory cascades.
A number of upregulated inflammatory and oncogenic path-
ways in PDAC converge on the transcription factors STAT3 and
NF-kB, suggesting that these are excellent therapeutic targets. Two
recent studies have demonstrated upregulation of STAT3 in PDAC
(Fukuda et al, 2011; Lesina et al, 2011). Using mouse models of
endogenous mutant Kras plus experimentally induced pancreatitis,
the authors observed STAT3 activation in response to acinar
damage. Activation was only sustained in the setting of Kras-
accelerated metaplastic ducts and PanIN formation. When STAT3
was deleted, specifically within the pancreas, this significantly
interfered with inflammation-mediated PanIN formation, and
reduced both inflammatory cell infiltration (CD45þ cells) and
cytokine expression including IL-6. Candidate ligands for activa-
tion of STAT3 signalling in these model tumours were inter-
rogated, and IL-6 was significantly upregulated and expressed
predominantly by infiltrating macrophages. In human PDAC,
serum IL-6 levels were significantly raised suggesting a potential
link between systemic inflammation and PDAC tumorigenesis.
Importantly IL-6 activation can occur via trans-signalling when
IL-6 binds to a naturally occurring soluble form of IL-6R and
forms a complex that induces IL-6-specific signalling in cells that
lack a membrane-bound receptor. Indeed this latter form of
signalling was found to be critical in the process of PDAC
tumorigenesis. Furthermore Corcoran et al (2011) have established
that pSTAT3 levels predict PDAC cell sensitivity to JAK2
inhibition, suggesting pSTAT3 status may be used in future to
select patients for JAK/STAT inhibition.
Several studies have shown NF-kB signalling to be an important
signalling node in pancreatic cancer. In chronic inflammation-
associated PDAC, NF-kB expression leads to secretion of the pro-
tumorigenic Shh ligand by macrophages (Yamasaki et al, 2010).
When stimulated by cytokines such as TNF-a, NF-kB activates
expression of growth-promoting molecules including cyclin D1
and E, c-Myc and IL-6. There is also evidence that mutant KRAS
can activate NF-kB through IL-1a and p62. Meilisi et al identified
autocrine IL-1a secretion from PDAC cells to be the mechanism of
constitutive NF-kB activation. They showed that in response to
IL-1a stimulation, PDAC cells exhibited an invasive phenotype
in vitro and when injected orthotopically into the murine pancreas
generated liver metastases. This phenotype was reversed upon
inhibition of NF-kB (Melisi et al, 2009). Interestingly IKK2/b, a
kinase required to release NF-kB from inhibition, is necessary for
the induction of CP, and PanIN and PDAC formation following
Kras mutation (Ling, 2012). When genetically inactivated in a
normally rapid mouse model of PDAC driven by mutant Kras and
conditional deletion of Cdkn2a, mice fail to develop PDAC over a
1-year period. In addition, proliferation was significantly reduced
in Pdx1-Cre; KrasG12D/þ ; IKK2/Bfl/fl animals compared with Pdx1-
Cre; KrasG12D/þ controls. Further, the inflammatory infiltrate seen
in Pdx1-Cre; KrasG12D/þ controls, which included T and B cells,
macrophages and neutrophils, was not observed in Pdx1-Cre;
KrasG12D/þ ; IKK2/Bfl/fl animals. These observations provide further
evidence supporting a role for inflammation in PDAC develop-
ment and a critical role for NF-kB in this process.
Thus, murine models have provided compelling evidence for
the dependence of PDAC initiation on intrinsically generated
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inflammation. The activation of NF-kB and STAT3 signalling by
upregulated systemic cytokines including IL-6, IL-1a, and TNF-a
identifies many of these molecules as excellent therapeutic targets.
Anti-TNF-a therapies such as infliximab are well established in
inflammatory conditions such as inflammatory bowel disease.
Egberts et al (2008) demonstrated in orthotopic PDAC models that
anti-TNF therapy reduced primary tumour size and metastases,
however, these results have not been translated to clinical trials.
Targeting IL-6, a recognised mediator of PDAC tumorigenesis,
may be of therapeutic benefit. IL-6 monoclonal antibodies,
Siltuximab and Tocilizumab, which bind to the soluble form of
the IL-6 receptor are available for trial and currently under
assessment in ovarian cancer (clinicaltrials.gov). Furthermore, key
nodes in the transmission of inflammatory signals such as STAT3,
which is strongly implicated in PDAC tumorigenesis, can now be
targeted with direct inhibitors. Recently triterpenoids and rexinoids
demonstrated good efficacy in STAT3 binding, and prolonged
survival in the KrasG12D; p53fl/þ mouse model (Liby et al, 2010).
These studies suggest that the repositioning of some anti-
inflammatory to treat pancreatic cancer may offer clinical benefit
in the future.
COOPERATION BETWEEN TSG MUTATION AND
CHEMOKINE SIGNALLING IN PDAC PROGRESSION
Recent studies support the deregulation of CXC chemokines in late-
stage PDAC. Mutation of p53 can drive migration and metastasis in
PDAC and this process was recently shown to be dependent on NF-
kB signalling downstream of CXCR2 ligand upregulation (Li et al,
2011). In addition, CXCL5, a ligand for CXCR2, was overexpressed
in human PDAC and marked patients with poor outcome, advanced
tumour stage and increased tumour size. Chemokine signalling may
be critical in promoting invasion and metastasis in PDAC, especially
downstream of mutations in TP53.
Chemokine signalling may also be deregulated by SMAD4
mutations, found in 50% of PDAC cases (Rozenblum et al, 1997).
SMAD4 is a TGF-b signalling molecule, and its loss is thought to
influence PDAC tumorigenesis through coordination of TGF-b
signalling in the tumour and stroma, as both fibroblasts and
epithelial cells respond to TGF-b in the tumour microenvironment
(Ijichi et al, 2011). In a mutant Kras mouse model, Ijichi et al
(2011) demonstrated that TGF-b receptor II knockout resulted in
aggressive PDAC that histologically recapitulated human disease.
Secretion of CXCR2 specific chemokines, including CXCL1 and
CXCL5, was significantly increased in these mice, and regulated by
TGF-b signalling and NF-kB. Interestingly, stromal fibroblasts also
expressed significantly higher CXCR2 levels compared with
epithelial cells. Treatment with a CXCR2 inhibitor over a short
period improved survival and reduced microvessel density,
supporting the theory that CXCR2 ligands are important in
driving tumour progression following TSG mutation in PDAC.
These studies support the notion that pro-inflammatory path-
ways can be regulated by multiple different driver mutations in
PDAC. The prognostic significance of deregulated chemokines and
the functional role they have following TSG mutation, together
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Figure 2. Targeting inflammation in the treatment of PDAC. Schematic illustrating progression to PDAC through PanIN stages, with potential
therapeutic opportunities in both prevention and treatment of disease outlined.
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with the successful use of their inhibitors in other diseases, suggest
that chemokines are potentially exciting therapeutic targets in
patients with PDAC.
METASTASIS AND INFLAMMATION
Recent studies have shown metastases may occur in PDAC even
before a primary tumour has formed, a behaviour associated with
early epidermal mesenchymal transformation (Rhim et al, 2012). This
process was accelerated in the presence of pancreatic inflammation,
while the most invasive areas of tumour were seen at foci of
inflammation. This phenotype was suppressed by dexamethasone,
highlighting the integral role played by tumoural inflammation.
CXCR2 has been shown to be an important pro-survival factor in
metastatic breast cancer models (Acharyya et al, 2012). CXCR2
inhibition in this setting sensitised metastases to killing by standard
chemotherapeutics. Chemokine-specific small molecules and mono-
clonal antibodies are undergoing preclinical study at present. The
identification of inflammatory signalling pathways in the generation
and maintenance of metastases in PDAC provides hope for
combinatory anti-metastatic therapies in the near future.
CONCLUSIONS
Treating PDAC by targeting its reliance on the tumour micro-
environment may be approached from three aspects (Figure 2):
first by promotion of tumour-eliminating processes; second by
suppression of tumour-promoting inflammation; and third via
modulation of the protective fibrotic stroma of PDAC to allow
access to tumour epithelium by conventional chemotherapeutics.
The availability of preclinical in vivo models that accurately
recapitulate the histological progression of PDAC and its complex
microenvironment provides an excellent tool linking basic science
with clinical application. The potential for preoperative character-
isation of PDAC and direction of tumour-specific individualised
therapy is within sight. Individualised multi-targeted therapy is
likely to be necessary in order to treat PDAC effectively, as high
recurrence rates following surgery and late presentation of disease
remain significant hurdles.
Only 10–15% of PDAC are resectable at presentation high-
lighting that one of the greatest challenges facing PDAC manage-
ment is earlier diagnosis. However, even those with R0 resection
margins following surgery sadly suffer disease recurrence despite
adjuvant therapy, often due to acquired drug resistance.
We have outlined the importance of the activated tumour
microenvironment in PDAC maintenance and progression.
Inflammation is implicated in the earliest stages of PDAC
tumorigenesis, is strongly implicated in early metastases, and in
tumour progression following TSG mutation. Combinatorial
therapeutic regimens must look to capitalise on the importance
of this tumour–microenvironment relationship. Aggressive tar-
geted neoadjuvant therapy in surgically resectable patients should
be considered, while those with more advanced disease may well
respond to similar regimens. Incorporating newly developed anti-
inflammatory agents alongside standard chemotherapeutics may
help provide much needed improvement in tumour sensitivity to
therapy for patients suffering PDAC.
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